NBY vs. CLDI, RLYB, NKGN, HOTH, NXTC, IMNN, NERV, BCTX, BGXX, and CLRB
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Calidi Biotherapeutics (CLDI), Rallybio (RLYB), NKGen Biotech (NKGN), Hoth Therapeutics (HOTH), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs.
Calidi Biotherapeutics (NYSE:CLDI) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
NovaBay Pharmaceuticals has higher revenue and earnings than Calidi Biotherapeutics.
Calidi Biotherapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 2,315.46%. NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential upside of 49.91%. Given Calidi Biotherapeutics' higher probable upside, research analysts clearly believe Calidi Biotherapeutics is more favorable than NovaBay Pharmaceuticals.
12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Calidi Biotherapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
NovaBay Pharmaceuticals received 1 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users.
Calidi Biotherapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Calidi Biotherapeutics' return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.
In the previous week, Calidi Biotherapeutics had 1 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 2 mentions for Calidi Biotherapeutics and 1 mentions for NovaBay Pharmaceuticals. Calidi Biotherapeutics' average media sentiment score of 0.23 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media.
Summary
Calidi Biotherapeutics beats NovaBay Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy NBY Stock Free NBY Stock Alerts